Jazz's Ziihera cleared for first-line gastric cancer use
The FDA has expanded the approval of Jazz Pharmaceuticals' bispecific antibody Ziihera to include certain patients with gastric cancer. This is the first time the drug is indicated for newly diagnosed patients, building on its 2024 approval for a different patient group.
Related stories
Bispecific Antibody Regimen Approved for HER2-Positive Upper GI Cancers · Drug development
J&J's Imaavy becomes first approved therapy for rare anemia · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “FDA approves Jazz's Ziihera in frontline gastric cancer.” Browse more stories.